Therapeutic Insights
Filter News
Found 736 articles
-
“The recent progress of cystic fibrosis drugs has been amazing and, in my case, miraculous,” said Kelly Peters, who lives with cystic fibrosis. “The new drugs are not a cure, but they feel pretty close.” -
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report. -
*Achoo* Muddling through a stuffy, runny nose and itchy, watery eyes? You aren’t alone - over 17.6 million American adults (about 7.5%) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as ... -
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv... -
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract. -
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im... -
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook. -
The annual Alzheimer’s Association International Conference (AAIC) is running from July 31-August 4 at the San Diego Convention Center and online. Here are some of the highlights presented so far.
-
Diadem Presents Data at 2022 Alzheimer's Association International Conference® Showing Its Blood-Based Biomarker Test Can Both Diagnose and Predict Alzheimer's Disease
8/2/2022
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer's disease (AD), today reported that study data presented at the Alzheimer's Association International Conference® 2022 (AAIC®) in San Diego.
-
Lower Socioeconomic Status in Childhood, Persistent Low Wages Linked to Risk for Dementia and Faster Memory Decline
8/2/2022
Socioeconomic deprivation, including neighborhood disadvantages and persistent low wages, are associated with higher dementia risk, lower cognitive performance and faster memory decline, according to several studies reported at the Alzheimer's Association International Conference® 2022 in San Diego and virtually.
-
AlzeCure Presents New Clinical Data with NeuroRestore ACD856 at the Alzheimer's Conference AAIC
8/2/2022
AlzeCure Pharma AB announced that the company's presentation at the Alzheimer's conference AAIC 2022, regarding new clinical data with its leading drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer's disease, is now available in its entirety on the company's website.
-
Vicinitas launched with a Series A round worth $65 million and was co-led by a16z and Deerfield Management, with participants including Droia Ventures, GV, and the Berkeley Catalyst Fund. -
The ongoing AAIC 2022 in San Diego has delivered positive news for the AD space. We look at updates from Vivoryon, Anavex and Argentinian scientists below.
-
Seven Researchers Honored for Scientific Achievements and Contributions to the Dementia Field at Alzheimer's Association International Conference
8/1/2022
The Alzheimer's Association® will present seven awards at the Alzheimer's Association International Conference® 2022, recognizing researchers for their varied expertise, noteworthy achievements and innovative contributions to the field of Alzheimer's and dementia science.
-
Ashvattha Therapeutics Announces Preclinical Data at the 2022 AAIC Demonstrating its Hydroxyl Dendrimer-Based Imaging Agent [18F]OP-801 Can Detect Early-Stage Neuroinflammation with a Higher Sensitivity Than TSPO-PET
8/1/2022
Ashvattha Therapeutics announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer -based PET tracer, [18F]OP-801, can detect neuroinflammation via activated microglia and macrophages with higher sensitivity than translocator protein 18 kDa [TSPO]-PET, using [18F]GE180, an established and validated PET imaging approach, in a mouse model of Alzheimer’s Disease.
-
Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates at the 2022 Alzheimer's Association International Conference (AAIC)
8/1/2022
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau protein for Alzheimer’s disease (AD) during a poster session at the 2022 Alzheimer's Association International Conference (AAIC).
-
Cognito Therapeutics Announces Proprietary Gamma Sensory Stimulation for 6-Months Reduces White Matter Atrophy in Alzheimer’s Disease Patients
8/1/2022
Cognito Therapeutics , announced today that its proprietary gamma sensory stimulation at 40Hz over a 6-month period reduced white matter atrophy in the brain for patients with Alzheimer’s Disease, according to new data presented at the Alzheimer’s Association International Conference 2022.
-
Annovis Bio to Participate on Alzheimer's Association International Conference Panel
8/1/2022
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced that Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis, will be participating on the Systems Biology of Alzheimer's Disease Panel at the Alzheimer's Association International Conference (AAIC).
-
C2N’s New Blood Test Combining p-tau217 Ratio with Aβ42/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment
7/31/2022
Data released from C2N Diagnostics, presented at the Alzheimer's Association International Conference, demonstrated that a blood test combining the Aβ42/40 ratio, a component of C2N’s commercially available PrecivityADTM blood test, with a unique p-tau217 ratio leads to testing performance that points to accuracy comparable to more complex amyloid PET imaging and invasive cerebrospinal fluid tests in identifying Alzheimer’s brain pathology.
-
Alzheimer's Association Global Workgroup Releases Recommendations About Use of Alzheimer's "Blood Tests"
7/31/2022
Alzheimer's disease blood biomarkers may revolutionize the diagnosis of Alzheimer's in the future, but are not yet ready for widespread use, according to a newly-published article by leading international clinicians and researchers convened by the Alzheimer's Association®.